中泰证券--万孚生物:医疗器械业绩高速增长,国内外疫情下新冠试剂盒带来较大业绩弹性【公司研究】

中泰证券2020-07-07

【研究报告内容摘要】事件:公司发布2020年中报业绩预告,预计实现归母净利润4.13-4.54亿元,同比增长100-120%。主业恢复+新冠国内外销售持续带来业绩进一步高速增长。根据业绩预告中值计算,2020H1公司实现归母净利润增速110%,较一季度有进一步的加速,其中2020Q2单季度实现归母净利润增速中值为151%,扣非净利润增速中值为160%,实现业绩的高速增长,主要原因是全球新冠疫情爆发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

奶奶的牛
2020-07-12
奶奶的牛
貂7你，这和康基什么关系？

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2049115447?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","is_english":false,"pubTime":"2020-07-07 09:44","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2049115447","market":"sh","top_or_hot":-1,"title":"中泰证券--万孚生物:医疗器械业绩高速增长,国内外疫情下新冠试剂盒带来较大业绩弹性【公司研究】","media":"中泰证券","content":"<div>\n<p>【研究报告内容摘要】事件:公司发布2020年中报业绩预告,预计实现归母净利润4.13-4.54亿元,同比增长100-120%。主业恢复+新冠国内外销售持续带来业绩进一步高速增长。根据业绩预告中值计算,2020H1公司实现归母净利润增速110%,较一季度有进一步的加速,其中2020Q2单季度实现归母净利润增速中值为151%,扣非净利润增速中值为160%,实现业绩的高速增长,主要原因是全球新冠疫情爆发...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20200707094704794ec97d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中泰证券--万孚生物:医疗器械业绩高速增长,国内外疫情下新冠试剂盒带来较大业绩弹性【公司研究】</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中泰证券--万孚生物:医疗器械业绩高速增长,国内外疫情下新冠试剂盒带来较大业绩弹性【公司研究】\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-07-07 09:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20200707094704794ec97d&s=b><strong>中泰证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【研究报告内容摘要】事件:公司发布2020年中报业绩预告,预计实现归母净利润4.13-4.54亿元,同比增长100-120%。主业恢复+新冠国内外销售持续带来业绩进一步高速增长。根据业绩预告中值计算,2020H1公司实现归母净利润增速110%,较一季度有进一步的加速,其中2020Q2单季度实现归母净利润增速中值为151%,扣非净利润增速中值为160%,实现业绩的高速增长,主要原因是全球新冠疫情爆发...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20200707094704794ec97d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20200707094704794ec97d&s=b","article_id":"2049115447","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20200707094704794ec97d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2049115447","pubTimestamp":1594086266,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"【研究报告内容摘要】事件:公司发布2020年中报业绩预告,预计实现归母净利润4.13-4.54亿元,同比增长100-120%。主业恢复+新冠国内外销售持续带来业绩进一步高速增长。根据业绩预告中值计算,","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300482":"万孚生物","600918":"中泰证券","09996":"沛嘉医疗-B","09997":"康基医疗"},"translate_title":"China-Thailand Securities-Wanfu Biology: Medical Device Performance Grows Rapidly, New Crown Kit Brings Greater Performance Flexibility under Domestic and Foreign Epidemic Situation [Company Research]","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300482":1,"600918":1,"09996":1,"09997":1},"content_text":"【研究报告内容摘要】事件:公司发布2020年中报业绩预告,预计实现归母净利润4.13-4.54亿元,同比增长100-120%。主业恢复+新冠国内外销售持续带来业绩进一步高速增长。根据业绩预告中值计算,2020H1公司实现归母净利润增速110%,较一季度有进一步的加速,其中2020Q2单季度实现归母净利润增速中值为151%,扣非净利润增速中值为160%,实现业绩的高速增长,主要原因是全球新冠疫情爆发,国内外市场对新型冠状病毒检测试剂的需求激增,带来较大业绩弹性;此外二季度开始国内疫情逐步好转,医院诊疗量开始恢复,公司传统业务中心标、感染等产品销售较一季度有进一步的回升。内需+出口共同催化下,新冠检测试剂盒有望持续带来较大业绩弹性。公司新冠产品是国内首批正式获准上市的新冠病毒抗体POCT试剂,再加上公司快速获得CE等海外市场准入,从二月份开始逐渐实现新冠产品在国内市场的销售,并陆续出口到海外市场。截止2020H1,公司新冠产品的销售已经覆盖了欧洲、亚洲、拉美超过70个国家和地区,为新冠疫情的全球战疫做出了突出的贡献,也为公司2020年上半年的业绩增长带来了强劲的动力。随着新冠疫情逐步常态化,我们预计新冠病毒检测有望像流感一样成为常规检测项目,持续为公司提供业绩增量。盈利预测与估值:考虑到新冠检测试剂对业绩影响较大,我们调整了未来三年盈利预测,我们预计2020-2022年公司收入43.11、41.10、49.54亿元,同比增长108.05%、-4.67%、20.54%,归母净利润9.68、8.51、10.87亿元,同比增长149.88%、-12.06%、27.65%,对应EPS为2.83、2.48、3.17。目前公司股价对应2021年40倍PE,考虑到公司是国内POCT龙头企业,中短期业绩受益疫情快速增长,长期在新产品驱动下有望保持高成长性,维持“买入”评级。风险提示:新产品研发、注册及认证风险,政策变化风险,汇率变动风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":943829633,"gmtCreate":1594516432822,"gmtModify":1704205825686,"author":{"id":"3474596929652921","authorId":"3474596929652921","name":"奶奶的牛","avatar":"https://static.tigerbbs.com/c8007f2519d56a428612e5ed64e0ebff","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3474596929652921","authorIdStr":"3474596929652921"},"htmlText":"貂7你，这和康基什么关系？","listText":"貂7你，这和康基什么关系？","text":"貂7你，这和康基什么关系？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/943829633","repostId":2049115447,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2049115447"}